Your details appear on your Certificate of Completion and are stored only on this device.
Optimal vs. standard reference ranges - what your results actually mean for metabolic health.
| Marker | Standard Range | Optimal Range | Why It Matters | Clinical Action |
|---|---|---|---|---|
Fasting Glucose EARLY MARKER | 70–99 mg/dL (normal) 100–125 mg/dL (pre-diabetes) | 72–85 mg/dL | Standard 'normal' extends to 99 mg/dL, but risk for T2D rises continuously above 85. A glucose of 95 is not the same as 75. | If 86–99 mg/dL, order fasting insulin and HOMA-IR. Do not wait for 100. |
Fasting Insulin EARLY MARKER | 2–25 mIU/L (lab-dependent; many labs don't flag until >25) | 2–5 mIU/L | Fasting insulin above 5 mIU/L indicates compensatory hyperinsulinemia - the pancreas is working harder than it should to maintain normal glucose. This is the earliest detectable sign of insulin resistance. | Order routinely alongside fasting glucose. Above 10 mIU/L warrants dietary intervention regardless of glucose. |
HOMA-IR EARLY MARKER | < 2.5 (most labs); often not reported | < 1.0 (ideal) 1.0–1.5 (acceptable) | HOMA-IR = (fasting glucose mg/dL × fasting insulin mIU/L) ÷ 405. A value of 1.5–2.5 indicates early insulin resistance. Above 2.5 is significant. Above 5.0 is severe. | Calculate manually if not reported. Share the number with the patient - it is highly motivating and easy to retest. |
HbA1c | < 5.7% (normal) 5.7–6.4% (pre-diabetes) ≥ 6.5% (diabetes) | < 5.3% | HbA1c reflects average glucose over 90 days. It lags behind insulin resistance by years. A 'normal' HbA1c of 5.6% can coexist with severe hyperinsulinemia. | Use HbA1c for monitoring, not early detection. Pair with fasting insulin for a complete picture. |
2-Hour Post-Glucose Insulin (Kraft Pattern) EARLY MARKER | < 140 mg/dL glucose at 2 hours | Insulin < 30 mIU/L at 2 hours (Pattern I) | Joseph Kraft's data on 14,000+ patients showed that the majority of people with normal fasting glucose have abnormal insulin response patterns during OGTT. Pattern II–V responses predict future T2D. | Consider insulin-augmented OGTT for patients with risk factors and normal fasting glucose/HbA1c. |
| Marker | Standard Range | Optimal Range | Why It Matters | Clinical Action |
|---|---|---|---|---|
Triglycerides EARLY MARKER | < 150 mg/dL (normal) 150–199 mg/dL (borderline high) | < 80 mg/dL | Fasting TG above 100 mg/dL reflects impaired fat clearance driven by hyperinsulinemia. Insulin normally suppresses hepatic VLDL production. Elevated TG is one of the earliest lipid markers of insulin resistance. | Use 80 mg/dL as the target, not 150. Elevated TG with low HDL is a strong metabolic risk signal. |
HDL Cholesterol | > 40 mg/dL (men) > 50 mg/dL (women) | > 60 mg/dL (men) > 70 mg/dL (women) | Low HDL is a consistent feature of insulin resistance. Elevated TG drives CETP-mediated exchange, depleting HDL particles. HDL below 40 (men) or 50 (women) is a metabolic syndrome criterion. | Evaluate in context of TG. Low HDL + high TG = high probability of insulin resistance and small dense LDL. |
TG:HDL Ratio EARLY MARKER | Not routinely reported | < 1.5 (ideal) < 2.0 (acceptable) | One of the most accessible and underused markers of insulin resistance. A ratio above 3.0 correlates strongly with hyperinsulinemia, small dense LDL, and cardiovascular risk. Calculate from the standard lipid panel. | Calculate at every lipid panel. Share with patients as a simple, actionable number. Above 3.0 warrants dietary intervention. |
LDL Cholesterol | < 100 mg/dL (optimal per ACC/AHA) | Context-dependent. Pattern A (large fluffy) LDL is not atherogenic. | Total LDL is a poor predictor of cardiovascular risk in isolation. Small dense LDL (Pattern B) is atherogenic; large fluffy LDL (Pattern A) is not. High TG:HDL ratio predicts Pattern B without advanced testing. | If TG:HDL > 3.0, assume Pattern B LDL. Consider NMR LipoProfile or VAP test for particle size if available. |
ApoB | < 100 mg/dL | < 80 mg/dL | ApoB measures the number of atherogenic particles (each VLDL, IDL, and LDL particle carries one ApoB). More predictive of cardiovascular risk than LDL-C in patients with metabolic syndrome. | Order ApoB in patients with metabolic syndrome, high TG, or low HDL. More actionable than LDL-C in this population. |
| Marker | Standard Range | Optimal Range | Why It Matters | Clinical Action |
|---|---|---|---|---|
hsCRP EARLY MARKER | < 3.0 mg/L (low risk per ACC/AHA) | < 0.5 mg/L | High-sensitivity CRP above 1.0 mg/L indicates low-grade systemic inflammation associated with visceral adiposity and insulin resistance. Visceral fat secretes IL-6, which drives hepatic CRP production. | Use < 1.0 mg/L as the metabolic target. Elevated hsCRP with normal lipids suggests visceral adiposity. Exclude infection/autoimmune before attributing to metabolic cause. |
Uric Acid EARLY MARKER | 2.4–7.0 mg/dL (men) 2.4–6.0 mg/dL (women) | < 5.0 mg/dL (men) < 4.5 mg/dL (women) | Elevated uric acid is an early marker of fructose metabolism and insulin resistance. Fructose metabolism generates uric acid as a byproduct. Uric acid inhibits endothelial nitric oxide, contributing to hypertension and endothelial dysfunction. | Order in all metabolic screening panels. Elevated uric acid often precedes gout, hypertension, and T2D by years. |
Ferritin | 12–300 ng/mL (men) 12–150 ng/mL (women) | 50–100 ng/mL | Ferritin is an acute-phase reactant elevated in metabolic syndrome and non-alcoholic fatty liver disease. Very high ferritin (> 300 in men, > 150 in women) in the context of metabolic syndrome suggests hepatic iron overload. | Evaluate in context. Low ferritin (< 30) suggests iron deficiency. High ferritin with elevated liver enzymes warrants hepatic evaluation. |
| Marker | Standard Range | Optimal Range | Why It Matters | Clinical Action |
|---|---|---|---|---|
ALT (Alanine Aminotransferase) EARLY MARKER | 7–56 U/L (men) 7–45 U/L (women) | < 25 U/L (men) < 19 U/L (women) | ALT is the most sensitive marker of hepatocellular injury. Elevated ALT in the context of metabolic syndrome suggests non-alcoholic fatty liver disease (NAFLD), which is present in ~75% of patients with T2D. | Use sex-specific optimal cutoffs. Elevated ALT + high TG + central adiposity = NAFLD until proven otherwise. |
GGT (Gamma-Glutamyl Transferase) | < 61 U/L (men) < 36 U/L (women) | < 20 U/L | GGT is elevated in NAFLD, alcohol use, and oxidative stress. It is an independent predictor of T2D and cardiovascular disease, even within the 'normal' range. | GGT above 20 U/L in a non-drinker warrants metabolic evaluation. Correlates with hepatic insulin resistance. |
eGFR | > 60 mL/min/1.73m² (normal) | > 90 mL/min/1.73m² | Chronic kidney disease is a common complication of metabolic syndrome and T2D. eGFR 60–90 is 'mildly reduced' but warrants monitoring and metabolic optimisation. | Monitor annually in patients with metabolic syndrome. Dietary intervention (low-carb) can slow CKD progression in T2D. |
Urine Albumin:Creatinine Ratio (UACR) EARLY MARKER | < 30 mg/g (normal) | < 10 mg/g | Microalbuminuria (30–300 mg/g) is the earliest sign of diabetic nephropathy and also a marker of endothelial dysfunction and cardiovascular risk. | Order annually in all patients with metabolic syndrome or T2D. Microalbuminuria warrants ACE inhibitor/ARB therapy and aggressive metabolic intervention. |
| Marker | Standard Range | Optimal Range | Why It Matters | Clinical Action |
|---|---|---|---|---|
Vitamin D (25-OH) | 30–100 ng/mL (sufficient per Endocrine Society) | 50–80 ng/mL | Vitamin D deficiency is associated with insulin resistance, metabolic syndrome, and T2D. Vitamin D receptors are present on pancreatic beta cells and immune cells. Deficiency impairs insulin secretion and increases inflammation. | Supplement to achieve 50–80 ng/mL. Most adults require 4,000–6,000 IU/day. Recheck in 3 months. |
TSH (Thyroid Stimulating Hormone) | 0.4–4.0 mIU/L | 0.5–2.0 mIU/L | Hypothyroidism causes insulin resistance, dyslipidaemia, and weight gain. Subclinical hypothyroidism (TSH 2.5–4.0) is common and often missed. Thyroid dysfunction can mimic or worsen metabolic syndrome. | If TSH > 2.5 with symptoms (fatigue, cold intolerance, weight gain), order free T4 and free T3. Consider treatment. |
Free Testosterone (men) | 9–30 ng/dL | > 15 ng/dL | Low testosterone is both a cause and consequence of insulin resistance and visceral adiposity. Adipose tissue converts testosterone to oestradiol via aromatase. Metabolic improvement often restores testosterone without hormone replacement. | If low, address metabolic syndrome first before considering TRT. Dietary intervention can raise testosterone significantly. |